The Effect of Lactobacillus reuteri Supplementation in Adults with Chronic Functional Constipation: a Randomized, Double-Blind, Placebo-Controlled Trial*

Ojetti,; Ianiro, Gianluca; Tortora, Annalisa; D’Angelo, Giovanna; Ta, Di Rienzo; Bibbò, Stefano; Migneco, Alessio; Gasbarrini, Antonio

doi:10.15403/jgld.2014.1121.234.elr

Cited by 106 publications

(78 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prototype Lactobacillus reuteri ATCC-PTA-6475 has been originally isolated from human's mother milk. Lactobacillus reuteri is considered a typical probiotic and was shown to ameliorate infectious and non-infectious gastrointestinal disorders in both humans and animals [ 34 - 36 ].…”

Section: Introductionmentioning

confidence: 99%

Beneficial bacteria inhibit cachexia

et al. 2016

View full text Add to dashboard Cite

Muscle wasting, known as cachexia, is a debilitating condition associated with chronic inflammation such as during cancer. Beneficial microbes have been shown to optimize systemic inflammatory tone during good health; however, interactions between microbes and host immunity in the context of cachexia are incompletely understood. Here we use mouse models to test roles for bacteria in muscle wasting syndromes. We find that feeding of a human commensal microbe, Lactobacillus reuteri, to mice is sufficient to lower systemic indices of inflammation and inhibit cachexia. Further, the microbial muscle-building phenomenon extends to normal aging as wild type animals exhibited increased growth hormone levels and up-regulation of transcription factor Forkhead Box N1 [FoxN1] associated with thymus gland retention and longevity. Interestingly, mice with a defective FoxN1 gene (athymic nude) fail to inhibit sarcopenia after L. reuteri therapy, indicating a FoxN1-mediated mechanism. In conclusion, symbiotic bacteria may serve to stimulate FoxN1 and thymic functions that regulate inflammation, offering possible alternatives for cachexia prevention and novel insights into roles for microbiota in mammalian ontogeny and phylogeny.

show abstract

Section: Introductionmentioning

confidence: 99%

Beneficial bacteria inhibit cachexia

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Recent evidence revealed that beneficial probiotics show promise for the treatment of disorder of small intestinal contractile activity caused by TBI [ 33 ]. Lactobacillus is one of the predominant probiotics in the animal’s GI tract which are defined as live microorganisms and when administered in adequate amounts, confer a health benefit to the host [ 5 , 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

The Effects of Lactobacillus acidophilus on the Intestinal Smooth Muscle Contraction through PKC/MLCK/MLC Signaling Pathway in TBI Mouse Model

Sun¹,

Hu²,

Fang³

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

Clinical studies have shown that probiotics influence gastrointestinal motility. However, the molecular mechanisms by which probiotic Lactobacillus modulates intestinal motility in traumatic brain injury (TBI) mouse model have not been explored. In the present study, we provided evidence showing that treatment of TBI mice with Lactobacillus acidophilus significantly improved the terminal ileum villus morphology, restored the impaired interstitial cells of Cajal (ICC) and the disrupted ICC networks after TBI, and prevented TBI-mediated inhibition of contractile activity in intestinal smooth muscle. Mechanistically, the decreased concentration of MLCK, phospho-MLC20 and phospho-MYPT1 and increased concentration of MLCP and PKC were observed after TBI, and these events mediated by TBI were efficiently prevented by Lactobacillus acidophilus application. These findings may provide a novel mechanistic basis for the application of Lactobacillus acidophilus in the treatment of TBI.

show abstract

“…Lactobacillus reuteri produces a broad-spectrum antimicrobial substance during fermentation of glycerol, which revealed that glycerol fermentation was associated with the production of beta-hydroxypropionic acid and trimethylene glycol [ 6 ]. L. reuteri is used as a probiotic for chronic constipation [ 7 ], inhibits Helicobacter pylori load in humans [ 8 ], and removes cholesterol [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Hypolipidemic Effects and Safety of Lactobacillus Reuteri 263 in a Hamster Model of Hyperlipidemia

Huang

Kan

et al. 2015

Nutrients

View full text Add to dashboard Cite

We aimed to verify the beneficial effects of probiotic strain Lactobacillus reuteri 263 (Lr263) on hypolipidemic action in hamsters with hyperlipidemia induced by a 0.2% cholesterol and 10% lard diet (i.e., high-cholesterol diet (HCD)). Male Golden Syrian hamsters were randomly divided into two groups: normal (n = 8), standard diet (control), and experimental (n = 32), a HCD. After a two-week induction followed by a six-week supplementation with Lr263, the 32 hyperlipidemic hamsters were divided into four groups (n = 8 per group) to receive vehicle or Lr263 by oral gavage at 2.1, 4.2, or 10.5 × 109 cells/kg/day for 6 weeks, designated the HCD, 1X, 2X and 5X groups, respectively. The efficacy and safety of Lr263 supplementation were evaluated by lipid profiles of serum, liver and feces and by clinical biochemistry and histopathology. HCD significantly increased serum levels of total cholesterol (TC), triacylglycerol (TG) cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), LDL-C/HDL-C ratio, hepatic and fetal TC and TG levels, and degree of fatty liver as compared with controls. Lr263 supplementation dose dependently increased serum HDL-C level and decreased serum TC, TG, LDL-C levels, LDL-C/HDL-C ratio, hepatic TC and TG levels, and fecal TG level. In addition, Lr263 supplementation had few subchronic toxic effects. Lr263 could be a potential agent with a hypolipidemic pharmacological effect.

show abstract

The Effect of Lactobacillus reuteri Supplementation in Adults with Chronic Functional Constipation: a Randomized, Double-Blind, Placebo-Controlled Trial*

Cited by 106 publications

References 23 publications

Beneficial bacteria inhibit cachexia

Beneficial bacteria inhibit cachexia

The Effects of Lactobacillus acidophilus on the Intestinal Smooth Muscle Contraction through PKC/MLCK/MLC Signaling Pathway in TBI Mouse Model

Hypolipidemic Effects and Safety of Lactobacillus Reuteri 263 in a Hamster Model of Hyperlipidemia

Contact Info

Product

Resources

About